Parallel Model Exploration for Tumor Treatment Simulations
Charilaos Akasiadis, Miguel Ponce-de-Leon, Arnau Montagud, Evangelos Michelioudakis, Alexia Atsidakou, Elias Alevizos, Alexander Artikis, Alfonso Valencia, Georgios Paliouras
Computational systems and methods are often being used in biological research, including the understanding of cancer and the development of treatments. Simulations of tumor growth and its response to different drugs are of particular importance, but also challenging complexity. The main challenges are first to calibrate the simulators so as to reproduce real-world cases, and second, to search for specific values of the parameter space concerning effective drug treatments. In this work, we combine a multi-scale simulator for tumor cell growth and a Genetic Algorithm (GA) as a heuristic search method for finding good parameter configurations in reasonable time. The two modules are integrated into a single workflow that can be executed in parallel on high performance computing infrastructures. In effect, the GA is used to calibrate the simulator, and then to explore different drug delivery schemes. Among these schemes, we aim to find those that minimize tumor cell size and the probability of emergence of drug resistant cells in the future. Experimental results illustrate the effectiveness and computational efficiency of the approach.
Can tumor location on pre-treatment MRI predict likelihood of pseudo-progression versus tumor recurrence in Glioblastoma? A feasibility study
Case Western Reserve University(凯斯西储大学);Cleveland Clinic(克利夫兰诊所)
胶质母细胞瘤(GBM)管理中的一个重大挑战是在常规治疗后的常规成像中识别肿瘤复发的假进展(PsP),这是一种良性辐射诱导效应。先前的研究已经将肿瘤叶的存在和偏侧性与GBM结果联系起来,表明GBM中的疾病病因和进展可能受到肿瘤位置的影响。因此,在这项可行性研究中,我们试图研究以下问题:初治MRI上的肿瘤位置是否可以提供有关患者发生假性进展与肿瘤复发可能性的早期线索?在这项研究中,分析了74例治疗前胶质母细胞瘤MRI扫描,其中PsP(33例)和肿瘤复发(41例)。首先,Gd-T1 w MRI增强病灶和T2 w/FLAIR病灶周围高信号由专家分割,然后配准到脑图谱。使用来自两种表型的患者,我们通过量化增强病变和病变周围高信号的发生频率,通过对整个人群的体素强度进行平均来构建两个图谱。然后进行差异参与分析,以计算各图谱之间的体素显着差异(p值<0.05)。最后将统计学上显著的聚类映射到结构图谱中,以提供其位置的解剖定位。我们的研究结果表明,肿瘤复发的患者表现出突出的顶叶的初始肿瘤,而PsP患者表现出多灶性分布的初始肿瘤在额叶和颞叶,颞叶和壳核。这些初步结果表明,治疗前病变向大脑某些解剖区域的偏侧化可以提供有关评估MRI扫描上肿瘤复发发生假性进展的可能性的早期线索。
Utilization of 3D segmentation for measurement of pediatric brain tumor outcomes after treatment: review of available free tools, step-by-step instructions, and applications to clinical practice
A stochastic agent-based model for simulating tumor-immune dynamics and evaluating therapeutic strategies
School of Software, Tiangong University(天津工业大学软件学院);School of Mathematical Sciences, Tiangong University(天津工业大学数学科学学院);Center for Applied Mathematics, Tiangong University(天津工业大学应用数学中心)
Novel Radiomic Measurements of Tumor- Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers
Case Western Reserve University(凯斯西储大学);Picture Health(Picture Health公司);Stony Brook University(石溪大学);University Hospitals Cleveland Medical Center(克利夫兰大学医院医学中心);Yale School of Medicine(耶鲁医学院);The Cleveland Clinic Foundation (CCF)(克利夫兰诊所基金会(CCF));New York University (NYU) Langone Medical Center(纽约大学(NYU)朗格尼医学中心);Louis Stokes Cleveland Veterans Medical Center(路易斯·斯托克斯克利夫兰退伍军人医学中心)
目的:肿瘤相关血管系统与健康血管的不同之处在于其混乱的结构和扭曲性,这会促进治疗抵抗。这些属性的可测量差异可能有助于根据全身治疗(例如化疗)的可能获益对患者进行分层。在这项工作中,我们提出了一类新的放射性生物标志物,称为定量肿瘤相关血管系统(QuanTAV)特征,并证明了它们预测多种癌症,成像方式和治疗方案的反应和生存的能力。实验设计:我们对558名患者的常规治疗前放射学(CT或对比增强MRI)进行了肿瘤血管分割并计算了扭曲和组织的数学测量值,这些患者接受了乳腺癌(n=371)或非小细胞肺癌(NSCLC,n=187)的四种一线化疗治疗干预策略之一。结果如下:在4种基于化疗的治疗策略中,QuanTAV测量的分类器显著(p<0.05)预测了单独保持测试队列的反应(AUC=0.63-0.71),并且当添加到单独的重要临床变量模型中时,AUC增加了0.06-0.12。QuanTAV风险评分是乳腺癌化疗(p=0.002,HR=1.25,95% CI 1.08-1.44,C指数= 0.66)和NSCLC放化疗(p=0.039,HR=1.28,95% CI 1.01-1.62,C指数=0.66)治疗队列中无复发生存期的预后指标。在所有治疗组中,包括接受化疗的NSCLC患者(p=0.034,HR=2.29,95% CI 1.07-4.94,C指数=0.62),分类QuanTAV风险组具有独立预后。…
Individualizing Glioma Radiotherapy Planning by Optimization of Data and Physics-Informed Discrete Loss
University of Zurich(苏黎世大学);Technical University of Munich(慕尼黑工业大学);Harvard University(哈佛大学);ETH Zurich(苏黎世联邦理工学院);Zuse Institute(祖斯研究所);University of California, Irvine(加州大学尔湾分校);TUM School of Medicine and Health(TUM医学院与健康学院)